ARTICLE | Emerging Company Profile

Harnessing homology

How Homology could target and edit genomes in vivo without cutting DNA

May 2, 2016 7:00 AM UTC

Homology Medicines Inc. is set to spin out of 5AM Ventures' incubator this week with a $43.5 million series A round and a gene editing platform that could be the first to provide targeted in vivo delivery of corrective genes without introducing artificial breaks in the genome.

Homology's technology allows the company to edit genomes via targeted homologous recombination using a novel class of adeno-associated viral (AAV) vectors. ...